Beyond Air Inc (XAIR)
NASDAQ:XAIR
XAIR Stock Chart & Stats
$0.71
-$0.04(-9.27%)
At close: 4:00 PM EST
$0.71
-$0.04(-9.27%)
Day’s Range― - ―
52-Week Range$0.65 - $5.84
Previous CloseN/A
Volume845.14K
Average Volume (3M)208.38K
Market Cap
$7.47M
Enterprise Value$15.59M
Total Cash (Recent Filing)$17.85M
Total Debt (Recent Filing)$24.82M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Jun 29, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding10,529,344
10 Day Avg. Volume184,376
30 Day Avg. Volume208,385
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.36
Price to Sales (P/S)4.98
P/FCF Ratio-0.42
Enterprise Value/Market Cap2.09
Enterprise Value/Revenue2.25
Enterprise Value/Gross Profit123.71
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$3.50Price Target Upside392.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.81
Revenue Forecast (FY)$12.74M
Bulls Say, Bears Say
Bulls Say
Clinical AdoptionPositive feedback from healthcare professionals and incorporation of the LungFit PH system into key opinion leaders' clinical workflows indicates real-world utility that could remove adoption barriers and support wider hospital uptake.
Funding And LiquidityPrivate placement proceeds combined with controlled operating expenses extend cash runway and reduce financing pressure while focusing resources on commercializing the next-generation LungFit PH device.
LeadershipAppointment of Robert Goodman as CEO, a commercial leader with a track record of ramping sales at medical technology companies, could accelerate sales execution and improve market penetration for the LungFit PH system.
Bears Say
Deal TerminationTermination of the agreement to sell NeuroNOS to XTL removes a potential source of non-dilutive cash and eliminates expected milestone payments and strategic partnership benefits.
Demand PostponementSome hospitals may defer purchases of the current LungFit PH device while awaiting the second-generation model, which could weaken revenue momentum and slow commercial traction.
Regulatory And Execution RiskUncertainty around regulatory approvals for expanded indications and commercialization creates execution risk that could limit revenue growth and suppress investor confidence.
Beyond Air News
XAIR FAQ
What was Beyond Air Inc’s price range in the past 12 months?
Beyond Air Inc lowest stock price was $0.65 and its highest was $5.84 in the past 12 months.
What is Beyond Air Inc’s market cap?
Beyond Air Inc’s market cap is $7.47M.
When is Beyond Air Inc’s upcoming earnings report date?
Beyond Air Inc’s upcoming earnings report date is Jun 29, 2026 which is in 84 days.
How were Beyond Air Inc’s earnings last quarter?
Beyond Air Inc released its earnings results on Feb 13, 2026. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.75 by -$0.1.
Is Beyond Air Inc overvalued?
According to Wall Street analysts Beyond Air Inc’s price is currently Undervalued.
Does Beyond Air Inc pay dividends?
Beyond Air Inc does not currently pay dividends.
What is Beyond Air Inc’s EPS estimate?
Beyond Air Inc’s EPS estimate is -0.54.
How many shares outstanding does Beyond Air Inc have?
Beyond Air Inc has 10,529,344 shares outstanding.
What happened to Beyond Air Inc’s price movement after its last earnings report?
Beyond Air Inc reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.75. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of Beyond Air Inc?
Currently, no hedge funds are holding shares in XAIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyond Air Inc
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
XAIR Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational momentum: double‑digit sequential growth, a 105% year‑over‑year revenue increase, a gross profit turnaround, significant cuts to operating costs (36% YoY) and extended commercial reach (45+ hospitals, VA sale, GPO coverage and 40-country distribution). Management secured additional capital and a pending NeuroNOS transaction that could de‑risk noncore R&D and create upside. Primary risks discussed were continued unprofitability and cash burn despite improvement, low absolute revenue and current gross margins, dependence on a contract manufacturer inspection and FDA timing for Gen II, lengthy sales cycles, and pending/contingent aspects of financing and the NeuroNOS sale. On balance the positive operational and financial momentum and progress toward Gen II and commercialization outweighed the remaining challenges.View all XAIR earnings summariesXAIR Stock 12 Month Forecast
Average Price Target
$3.50
▲(392.96% Upside)
Technical Analysis
Pulmonx
―
Hyperfine
―
TriSalus Life Sciences
―
Inspira Technologies Oxy BHN
―
Envoy Medical
―
Ownership Overview
Currently, No data available
---